GlassScriptPhysician profile
Kevin L Glancy
NPI 1790850345
$4,791.59
in general payments reported to CMS, 2019-2025
12 companies · $477 in 2025
The $477 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,310 · 2020: $319 · 2021: $571 · 2022: $578 · 2023: $152 · 2024: $385 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987 · Entertainment: $26.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.31 |
| Entertainment | $26.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,132.75 | 2019-2021 | |
| Alcon Vision LLC | $1,204.89 | 2019-2025 | Precision7, Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $414.62 | 2022-2025 | Infuse Multifocal, Infuse, Miebo |
| Johnson & Johnson Vision Care, INC. | $282.33 | 2020-2025 | Acuvue |
| Regeneron Healthcare Solutions, INC. | $244.37 | 2022-2024 | Eylea Hd |
| Allergan, INC. | $132.80 | 2022 | |
| Astellas Pharma US INC | $105.27 | 2025 | Izervay |
| Abbvie INC. | $99.97 | 2025 | |
| Alimera Sciences, INC. | $75.78 | 2019 | |
| Glaukos Corporation | $40.10 | 2022 | |
| Optos, INC. | $37.73 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abb Con-Cise Optical Group LLC | $20.98 | 2025 | Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Glancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.